[Effect of SU11248 on leukemia cell line K562 and its molecular mechanisms]

Ling-Qing Luo1, Xiao Cheng2, Yan Chen1

  • 1Department of Laboratorial Examination, Fujian Tumor Hospital of Fujian Medical University Teaching Hospital, Fuzhou 350014, Fujian Province, China.

Insights

SU11248 effectively inhibits K562 leukemia cell growth and induces apoptosis. Its mechanism involves down-regulating C-MYC, hTERT, and BCR-ABL mRNA, and inhibiting Akt phosphorylation.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Leukemia cell line K562 is a model for studying leukemia.
  • Understanding the mechanisms of anti-leukemic agents is crucial for treatment development.

Purpose of the Study:

  • To investigate the anti-proliferative and pro-apoptotic effects of SU11248 on K562 cells.
  • To elucidate the underlying molecular mechanisms of SU11248 action.

Main Methods:

  • MTT assay for proliferation.
  • TUNEL assay and DNA laddering for apoptosis.
  • RT-PCR for mRNA expression (C-MYC, hTERT, BCR-ABL).
  • Western blot for protein expression (Akt, p-Akt).

Main Results:

  • SU11248 significantly inhibited K562 cell proliferation in a time-dependent manner.
  • SU11248 induced apoptosis in K562 cells dose- and time-dependently.
  • SU11248 reduced C-MYC, hTERT, and BCR-ABL mRNA levels and inhibited Akt phosphorylation.

Conclusions:

  • SU11248 demonstrates potent anti-leukemic activity against K562 cells in vitro.
  • The mechanism involves apoptosis induction and downregulation of key oncogenes and signaling pathways.
  • SU11248 shows potential as a therapeutic agent for leukemia.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K